cbdMD (YCBD) Net Cash Flow Growth (3y) (2019 - 2025)
cbdMD (YCBD) Net Cash Flow Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.66% |
| Sep 30, 2025 | 34.33% |
| Jun 30, 2025 | 42.86% |
| Mar 31, 2025 | 68.18% |
| Dec 31, 2024 | 58.43% |
| Sep 30, 2024 | -80.23% |
| Jun 30, 2024 | 27.27% |
| Mar 31, 2024 | 28.44% |
| Dec 31, 2023 | -26.43% |
| Sep 30, 2023 | -79.40% |
| Jun 30, 2023 | 87.69% |
| Mar 31, 2023 | -28.99% |
| Dec 31, 2022 | -48.48% |
| Sep 30, 2022 | 25.83% |
| Jun 30, 2022 | -36.46% |
| Mar 31, 2022 | -23.31% |
| Dec 31, 2021 | -55.93% |
| Sep 30, 2021 | 104.15% |
| Jun 30, 2021 | -54.27% |
| Mar 31, 2021 | -33.86% |